Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/temazepam/claim/c2fb2bf0-e464-480d-adf9-613fff384d9d

claim2026-07-18workinginconclusive

derived from · upstream

feeds · downstream

Closure of psx:substance/temazepam/claim/c2fb2bf0-e464-480d-adf9-613fff384d9d: 55 upstream, 144 downstream.

psx:substance/temazepam/claim/c2fb2bf0-e464-480d-adf9-613fff384d9d
├─ used  src/pmid:6145073  Hypnotic action of benzodiazepines: a possible mechanism
  ├─ informed_by  claim/8d795504-0dde-4337-b521-d03366d2ce70  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/628be0d1-d9be-4ddd-9d23-1fb5bf851569  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/50f81fea-7271-4157-83bd-250c76d1de70  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/7f958709-5f68-48cf-9475-b427786d142d  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/8f2c33b4-097b-42c5-b010-b3868bf19cf8  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/f073f0cb-affe-44e2-87e5-7df058a9f27d  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/24f98e1f-9893-46a0-8a7b-797cf3a28354  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/79bc917d-3f3e-4d3f-af1c-96cec52a2bc6  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/6a28c0d9-89fc-41c3-b6d0-a9c6caa77156  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/2b150b12-090a-40c2-998a-5f42030d29b1  Claim in pharmacology — inconclusive  working
    ├─ used  src/url:df7e35eb3648b782  Temazepam - StatPearls
    ├─ used  src/doi:10.2165/00003088-199121030-00002  Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly
    ├─ used  src/url:f4711ccff9a521e8  Temazepam capsules: what was the problem?
    ├─ used  src/pmid:39304187  Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial
    ├─ used  src/doi:10.3810/pgm.2013.07.2684  Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use
    ├─ used  src/pmid:2868823  Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal
    ├─ used  src/pmid:7919947  Anxiolytic drugs: dependence, addiction and abuse
    ├─ used  src/pmid:8063932  Limb ischaemia after intra-arterial injection of Temazepam gel: histology of nine cases
    ├─ used  src/pmid:598411  Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules
    ├─ used  src/pmid:41540  Bioavailability of temazepam in soft gelatin capsules
    ├─ used  src/pmid:41539  Pharmacokinetics and metabolism of temazepam in man and several animal species
    ├─ used  src/pmid:8454086  Intra-arterial injection of temazepam in drug abusers
    ├─ used  src/pmid:11587866  Drug related deaths in the Strathclyde region of Scotland, 1995-1998
    ├─ used  src/doi:10.5664/jcsm.6470  Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
    ├─ used  src/doi:10.1111/jsr.14035  The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
    ├─ used  src/pmid:5391  Temazepam — PubChem Compound
    ├─ used  src/url:81e07470b5a2b614  Temazepam physical/chemical properties (CAS 846-50-4)
    ├─ used  src/pmid:6132933  Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effects
    ├─ used  src/doi:10.1055/s-0043-116492  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
    ├─ used  src/pmid:2891534  Pharmacokinetics of temazepam after day-time and night-time oral administration
    ├─ used  src/pmid:8329784  Bioavailability of temazepam: comparison of four 7.5-MG capsules with a single 30-MG capsule
    ├─ used  src/pmid:2858279  Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics
    ├─ used  src/doi:10.1016/j.clinthera.2016.09.010  Review of Safety and Efficacy of Sleep Medicines in Older Adults
    ├─ used  src/doi:10.1097/JCP.0b013e31816a9e4f
    ├─ used  src/pmid:2230060  A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia
    ├─ used  src/pmid:15119980  Comparison of temazepam 7.5 mg with temazepam 15 mg for the treatment of transient insomnia
    ├─ used  src/pmid:2892863  Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months
    ├─ used  src/pmid:2569887  Effects of temazepam premedication on cognitive recovery following alfentanil-propofol anaesthesia
    ├─ used  src/pmid:1683183  Adrenergic modulation of preoperative anxiety: a comparison of temazepam, clonidine, and timolol
    ├─ used  src/pmid:6123281  Temazepam as premedication in elderly patients
    ├─ used  src/doi:10.1136/bmj.38623.768588.47  Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
    ├─ used  src/pmid:1391671  A double-blind comparison of the effects of temazepam and triazolam on residual, daytime performance in elderly insomniacs
    ├─ used  src/doi:10.1016/j.rmed.2009.10.022  Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD
    ├─ used  src/doi:10.1016/j.sleep.2018.06.017  Pharmacological agents for improving sleep quality at high altitude: a systematic review and meta-analysis of randomized controlled trials
    ├─ used  src/pmid:24286360  Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial
    ├─ used  src/pmid:15163440  Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study
    ├─ used  src/pmid:10612270  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience
    ├─ used  src/pmid:8598503  Sedative-hypnotic drugs and the risk of hip fracture
    ├─ used  src/doi:10.1016/j.smrv.2009.10.008  Effect of hypnotic drugs on body balance and standing steadiness
    ├─ used  src/doi:10.1111/bcpt.12434  Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses.
    ├─ used  src/pmid:6133446  Benzodiazepine withdrawal syndrome: a literature review and evaluation
    ├─ used  src/url:9b1fd1d1955cbb06  Temazepam - Legal status by jurisdiction
    ├─ derived_from  gen/7906c1e4-b058-4c60-92ea-175622c518b7  Generation — pipeline-v5
    └─ generated_by  pub/5e2ce35e-62b5-4a3e-80be-13d488ece90c  Publication — backfill
├─ informed_by  section/pharmacology.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/2977dc4f-02e1-4796-8136-8d03a9ff6e52  Claim in pharmacology — inconclusive  working
    ├─ derived_from  issue/notice@f86dcbf2f96f  Issued notice
    ├─ derived_from  issue/info_card@833f2165fa6a  Issued info_card
    ├─ derived_from  issue/emergency@dcd2ca271fbe  Issued emergency
    ├─ derived_from  issue/info_card@25c55f1c618b  Issued info_card
      ├─ used  claim/1a359e7e-3bd6-4671-8f08-e109e5329c0f  Claim in summary — inconclusive  working
      ├─ used  claim/90d410db-240e-4a2a-b72e-fd2bae19598e  Claim in safety — inconclusive  working
      ├─ used  claim/8b539927-eb28-4990-8b36-ef5c05a1ddf0  Claim in safety — inconclusive  working
      ├─ used  claim/20ad8f83-a0dd-4073-9459-8c617e090c5c  Claim in history — inconclusive  working
      ├─ used  claim/5c9e5d87-bb67-4930-b5bf-6e6a5d6f929a  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/8db8e1d2-97f1-4adb-bd29-5643b0ccaecc  Claim in summary — inconclusive  working
      ├─ used  claim/506a0bc8-e100-4a55-af8e-a3446b13bb28  Claim in safety — inconclusive  working
      ├─ used  claim/1fe2e229-378f-4fa6-928c-7d308218d264  Claim in safety — inconclusive  working
      ├─ used  claim/fbb0d37b-8220-4eac-b9ce-2222ac30a4ba  Claim in history — inconclusive  working
      ├─ used  claim/a06470df-5065-4266-ae50-43348a287864  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/1fc17cb6-55c1-49d6-8b61-9e62d85602c6  Claim in summary — inconclusive  working
      ├─ used  claim/c20adbb5-6b01-486b-9819-50978eafe436  Claim in summary — inconclusive  working
      ├─ used  claim/c6b8c2b0-e29c-4190-8728-3468447fcdad  Claim in summary — inconclusive  working
      ├─ used  claim/1d60c8c0-1f28-4120-82cf-e3c6babdf460  Claim in safety — inconclusive  working
      ├─ used  claim/aa3743a5-ffea-4a43-a7ff-d73c173e6595  Claim in safety — inconclusive  working
      ├─ used  claim/a1d5697b-ae61-48c9-88dd-27a053388968  Claim in safety — inconclusive  working
      ├─ used  claim/27eadc57-2a23-4f10-ba45-65bb5bc49585  Claim in summary — inconclusive  working
      ├─ used  claim/626ca06d-0259-4dbf-a31b-28f60a416ba7  Claim in safety — inconclusive  working
      ├─ used  claim/2ca26188-b2d8-441d-8ce6-2555146ab5c9  Claim in safety — inconclusive  working
      ├─ used  claim/a0c591f3-5cf8-4b7a-b340-b105d373f201  Claim in safety — inconclusive  working
      ├─ used  claim/86e94548-c19f-478a-9fc7-1ccd181296ab  Claim in summary — inconclusive  working
      ├─ used  claim/b0d0ef74-abdd-4426-862c-f87b2f36c9c7  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/e07fafb8-4164-467b-a8ae-e8630a2e7117  Claim in safety — inconclusive  working
      ├─ used  claim/457628e2-215a-4776-a5a6-fb834ae3556e  Claim in safety — inconclusive  working
      ├─ used  claim/03b7f838-903f-4d8f-8686-1157d77b66a8  Claim in neuroscience — inconclusive  working
      ├─ used  claim/80116704-02c3-4937-81da-c8790964a8db  Claim in summary — inconclusive  working
      ├─ used  claim/2c25335a-6b33-4c52-a848-e71d2743e6b5  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/57b51851-4b3a-4801-8fb0-9247517b9063  Claim in safety — inconclusive  working
      ├─ used  claim/0901f5e0-9ec7-46be-a3dc-74bfa925c327  Claim in safety — inconclusive  working
      ├─ used  claim/d0762242-ad4e-48a5-ae99-71868ea46f36  Claim in neuroscience — inconclusive  working
      ├─ used  claim/05c53223-9dce-4a09-9af0-4b025b311dd2  Claim in summary — inconclusive  working
      ├─ used  claim/51ef05ee-fd6c-44b4-86d4-daf701a0db38  Claim in safety — inconclusive  working
      ├─ used  claim/70c0d33e-d4cc-45bd-8c0f-30fabb744239  Claim in safety — inconclusive  working
      ├─ used  claim/d21d1166-92e7-4f32-93b9-d5d2e61a72ac  Claim in summary — partially_supported
      ├─ used  claim/8704d397-96ed-4aa0-af64-18164865ac99  Claim in safety — supported
      ├─ used  claim/ba1c0c07-c4c7-4c11-bc27-bf3746ee3f29  Claim in safety — partially_supported
      ├─ used  claim/de003d60-6614-4b47-aa5a-e7667b9bec6a  Claim in summary — inconclusive  working
      ├─ used  claim/d3442bfa-4d20-4aed-8585-4378eaa0d4b2  Claim in safety — inconclusive  working
      ├─ used  claim/d11d8a49-237f-4019-8011-25a1971b131a  Claim in summary — inconclusive  working
      ├─ used  claim/5242c4bd-3b8e-4cfd-af1e-219bb4016a37  Claim in safety — inconclusive  working
      ├─ used  claim/34d45f09-2128-4306-81c0-a3cdeee91e10  Claim in history — inconclusive  working
      ├─ used  claim/755cee2c-308c-41a9-8748-2a34f76db2d6  Claim in history — inconclusive  working
      ├─ used  claim/edd27734-090b-40e3-88e2-6a69c43222eb  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/1885082c-d6e9-4396-9a1a-f26d964c0172  Claim in history — inconclusive  working
      ├─ used  claim/ac3e604f-fe6b-4293-a107-a51a87f7c130  Claim in history — inconclusive  working
      ├─ used  claim/723316b4-99ed-4b66-8c34-8ce581a66ce4  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/97d4daad-c40d-4424-979d-c6d9550f019a  Claim in history — inconclusive  working
      ├─ used  claim/7c59abea-9417-43f6-bea2-a0553a1ca6b4  Claim in chemistry — inconclusive  working
      ├─ used  claim/1c259352-c54a-41bf-b36c-c3d8aac0a21c  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/4c76b8df-0bc7-45f9-ad2a-11ea807e8793  Claim in history — inconclusive  working
      ├─ used  claim/b205d338-9aec-4506-a059-e00569f0a063  Claim in chemistry — inconclusive  working
      ├─ used  claim/abe554bb-3c62-4b11-9d00-a2fa4424a5d4  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/34c57194-9856-4d1d-8930-1b40716fb1e2  Claim in safety — inconclusive  working
      ├─ used  claim/2aac46d7-e39c-4475-a457-63aea5d3ae82  Claim in history — inconclusive  working
      ├─ used  claim/f9f0230e-9847-4940-b180-4ffff5ebd80c  Claim in safety — inconclusive  working
      ├─ used  claim/61825326-5d03-4cb8-86b3-5ad041bb2e6a  Claim in history — inconclusive  working
      ├─ used  claim/5b88874d-5c84-462c-bb7a-99d49b0bd3c7  Claim in history — inconclusive  working
      ├─ used  claim/e6e5c0f3-5eb7-4924-9353-06c4c61ce4e5  Claim in history — inconclusive  working
      ├─ used  claim/834b8ea3-b400-492c-a263-dab8f8c467d7  Claim in history — inconclusive  working
      ├─ used  claim/2f1c9f64-be2a-42e7-a4c6-edbb38a55a66  Claim in history — supported
      ├─ used  claim/7d210f8b-237b-423b-9dad-19bfcaaddcdc  Claim in safety — inconclusive  working
      ├─ used  claim/ad778ffc-9305-41eb-bd3c-8e24f1f3e92b  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/3d18a435-8413-4b79-b88d-ffd9499fc6f5  Claim in safety — inconclusive  working
      ├─ used  claim/1efed75d-c618-4ace-ba0f-39ee03d5c385  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/82238e9d-4f8e-49c7-9efa-8023bedfa418  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/a1af1b35-3ba9-4415-9313-ffa7afc68ba6  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/8e58eeaf-b6a0-468e-b703-8aa88b8d96c8  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/29e5577c-f733-41e3-b6b9-74dfdbe80c2c  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/9737b4aa-a73b-4a74-bb1a-5d3a0269f6e7  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/c3d7d938-4f9e-4dd8-8a41-d9610ad0f799  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/ddee2e3e-a1ed-4e20-9583-d81581c70757  Claim in safety — inconclusive  working
      ├─ used  claim/dd57d2e1-7879-4a2a-ad8a-3b5376d5813d  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/cd5e3bbe-2134-4214-b630-319c6ddb799a  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/6749e85a-5c0d-4e21-a66e-54cb3b630e38  Claim in safety — inconclusive  working
      ├─ used  claim/c4c7f8c4-916c-46db-8c91-20ad4bb28763  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/c0639252-817d-4aa5-9ebf-8174bb8fa22d  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/ec34ac50-9b34-4b79-8421-e4e895f072a3  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/b39b2173-9311-4a5f-a9ae-5d23af1deb88  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/3f585bda-874c-47f2-8a7b-f70560b24569  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/3cbccfbd-e171-4316-96f3-eab21970853b  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/495bb268-d27f-4af4-a5bf-e498c1564373  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/25d48ea8-e329-4907-ae1d-63dd2c918100  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/13fc925a-145b-47d1-997e-96bef953f341  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/be518e68-4631-408a-a00f-97590b0fb865  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/786f1bb6-218a-4a29-8b7d-2927dfa40468  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/dc37c8c6-102a-435f-852a-ca19e53054de  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/0a22f3b7-1be5-46f5-bfb5-0ecb5716d245  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/f3d2f21e-b47a-43cd-9366-762f1538fae2  Claim in safety — inconclusive  working
      ├─ used  claim/bf394a75-1a62-493a-8953-6a780e6d9640  Claim in neuroscience — inconclusive  working
      ├─ used  claim/01f2be4f-c2db-407c-968f-0a2f2ab37b1e  Claim in neuroscience — inconclusive  working
      ├─ used  claim/d3c6bcdb-c257-435c-8d74-0b0bc039292c  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/86968acf-4ddb-4753-b625-4dcc47cb41be  Claim in safety — inconclusive  working
      ├─ used  claim/951699cb-fd3b-411e-a644-be9537e9a725  Claim in neuroscience — inconclusive  working
      ├─ used  claim/a6823cfa-4ddc-4de1-95ff-c874f3633b77  Claim in neuroscience — inconclusive  working
      ├─ used  claim/c82999a7-6b05-45c5-8d6f-ce9117a99173  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/9a7ab8bf-1541-4bd7-a042-17407af6c9a6  Claim in safety — inconclusive  working
      ├─ used  claim/10e31fb2-2c68-400f-964a-2028f15ffe24  Claim in neuroscience — inconclusive  working
      ├─ used  claim/91ce7922-7285-4895-b71a-2e2f5f79ab65  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/ef214f1c-2660-42df-8bce-474bbfa8e1d5  Claim in safety — inconclusive  working
      ├─ used  claim/2d95c45e-f998-4cbf-9538-51c867489709  Claim in neuroscience — inconclusive  working
      ├─ used  claim/1e3172e9-6c8f-45b0-acd1-d63a03d55ed0  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/2232d5ce-0eaf-4e06-9fc4-6c0f70528b66  Claim in neuroscience — inconclusive  working
      ├─ used  claim/a3235534-19af-440e-931a-3b8e63dcb6cb  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/b17ec4c1-883f-45c7-a1b8-181d05923e32  Claim in neuroscience — inconclusive  working
      ├─ used  claim/0c572e64-b997-49d4-9c07-5bb414cce46d  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/773cabbe-c059-4ddd-8d5b-32d134c02c36  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/18650516-e03e-41c0-961a-a87bd9c82354  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/8c89661b-47b3-4d18-8a6b-9de1b5ac458c  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/7eff19de-0bec-4c5b-bb9f-5f8a2f8b7b30  Claim in safety — inconclusive  working
      ├─ used  claim/78c3de42-a773-465f-b384-2d24c19f50eb  Claim in safety — inconclusive  working
      ├─ used  claim/31f12707-364c-41d6-a357-00ee85e5c831  Claim in safety — supported
      ├─ used  claim/8067b7e0-292d-4751-82cf-59226922f797  Claim in safety — supported
      ├─ used  claim/3113f228-85ce-4ecd-82f6-41c1030dc630  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/848f3aaf-dfac-4a70-977a-dbf299b36bbd  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/f4639409-4fd0-4c06-8da7-677eebf8b3a9  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/5ee0e711-9e4c-4eeb-9f6d-41b8c277f2b8  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/664bc6f1-dabc-4b49-9ddc-31bc463dc685  Claim in safety — inconclusive  working
      ├─ used  claim/b841ffdd-07f6-4733-8e71-35f37d0eedfc  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/4c435322-ef1b-4478-930e-eb66de9a279b  Claim in safety — inconclusive  working
      ├─ used  claim/a8d88588-93b7-4788-95f6-e82ef8a66651  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/8a325fb1-e496-434f-9f5e-d8ec88e7a2a5  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/26f66a5b-952c-4568-a727-aa75fc25893a  Claim in safety — inconclusive  working
      ├─ used  claim/babd36d9-68e3-45b2-9480-6ac70575e40f  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/3ea0f727-7f5a-4222-8a75-e8282e925efa  Claim in safety — inconclusive  working
      ├─ used  claim/c3ec0468-8d6c-4abd-868f-0ba6714ee9e7  Claim in safety — inconclusive  working
      ├─ used  claim/72a851bc-7356-446e-bde4-ac93a241c40a  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/c399401f-55e2-443e-91cc-d8bc2b4cfaa7  Claim in safety — inconclusive  working
      ├─ used  claim/956e2d22-ea8d-453b-a43d-20cd79d50c04  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/699bb16e-f4f3-4310-a821-5655596c4005  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/6b1dd6ea-892a-4923-ab78-4548fd1508ba  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/0a9bfd9d-af2e-4327-bd33-52c099db4393  Claim in safety — inconclusive  working
      ├─ used  claim/44d184ac-62b7-44f0-8aa1-0af6b5ae8a84  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/6ecdb75c-72fc-4b57-8340-0f8f5f0a49de  Claim in safety — inconclusive  working
      ├─ used  claim/8baebbcb-00cb-4c02-951a-42e365ed5a86  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/302f6da9-d526-4407-a828-d1ae8910ed7d  Claim in safety — inconclusive  working
      ├─ used  claim/aee31917-789b-4046-bc62-b19fd1188cbd  Claim in safety — inconclusive  working
      └─ used  claim/38c3dae8-679a-4869-b346-a356f9ee5fe6  Claim in safety — inconclusive  working
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

4312 with DOI

17 strong · 20 moderate · 6 weak

Compilations

12026-05-09T13:16:05.961Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

34last ruled 2026-06-04

1 awaiting a ruling

Issued documents

42026-10-19T20:34:07.457Z

notice · info card · emergency

Searches

200 with no results

queries and counts on the build

Claims checked

1548 supported

8 supported · 146 not

Correspondence

0received

consent field ships in Phase 4

Edges

417

derivations recorded for this entity

Complete over 43 sources, 1 compilation, and 34 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/temazepam/archive

2Build

one panel per compilation run

generation run 2026-05-09

59 min completedmodel pipeline-v5plan not recordedrun/1804f88d…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen128
selected by the model65
consumed as sources43

Verification

claims checked154
supported6
partially supported2
not supported0
inconclusive146
  • record
  • seen / partial
  • working

The model's own caveats

  • taper_protocol_well_supported
  • taper_note
  • taper_note

Reproduce

inputs
43 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
20 searches for this run
#sourcequeryseenkeptrationale
1ClinicalTrials.govtemazepam102Most directly relevant to temazepam efficacy and safety
2OpenAlextemazepam benzodiazepine hypnotic sleep insomnia103High-quality clinical guidelines and meta-analyses relevant to temazepam's therapeutic context
3PubMedtemazepam GABA-A receptor binding affinity benzodiazepine mechanism11Relevant to mechanism of action
4PubMedtemazepam dependence withdrawal addiction abuse42Relevant to dependence/withdrawal and abuse potential including IV injection problem
5PubChemtemazepam11Primary chemical identity source confirming seed data
6PubMedtemazepam pharmacokinetics bioavailability half-life metabolism106All directly relevant to temazepam PK parameters including half-life, bioavailability, Tmax, and dose forms
7PubMedtemazepam sleep insomnia efficacy clinical trial randomized105Directly relevant to temazepam efficacy in insomnia
8PubMedtemazepam preoperative premedication anxiety surgery84Clinical use context and cognitive effects data
9StatPearls/NCBI Bookshelftemazepam pharmacology pharmacokinetics15Key pharmacological and safety data from authoritative clinical reference
10Australian Prescribertemazepam capsule injection harm Australia UK13Primary narrative source for gelcap injection harm history
11Web Searchtemazepam legal status UK Australia Canada international controlled substance105Legal status in major jurisdictions
12Web Searchtemazepam gel capsule injection UK Scotland 1990s vascular complications harm history103Critical harm reduction context: gel capsule injection is a unique safety concern for temazepam
13Web Searchtemazepam discovery 1964 synthesis Hoffmann-La Roche history103Historical development context
14PubMedtemazepam benzodiazepine tolerance rebound insomnia withdrawal104—
15PubMedtemazepam placebo randomized insomnia efficacy sleep53—
16Web Searchtemazepam CAS number melting point solubility physical properties103—
17PubMedflumazenil benzodiazepine overdose reversal emergency52—
18Web Searchtemazepam first marketed FDA approval history Normison Restoril102—
19Multiple sourcestemazepam chemical identity cross-reference PubChem vs seed data15—
20PubChem REST APItemazepam SMILES InChI properties13—
154 claims by section — every cited sentence, checked against its source
safety50 · 5 ok

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • A meta-analysis of 24 RCTs found adverse cognitive events 4.78 times more common with sedative-hypnotics versus placebo in older adults (95% CI 1.47–15.47).supported

    Meta-analysis: sedative hypnotics including zolpidem improve sleep statistically but magnitude small. Increased adverse event risk (falls, cognitive impairment) in over-60s. bmj.38623.768588.47

  • A meta-analysis of 13 randomized controlled trials found significantly more adverse events with flumazenil versus placebo (RR 2.85) and more serious adverse events (RR 3.81), including supraventricular arrhythmia and convulsionssupported

    Meta-analysis of 13 RCTs (994 patients); flumazenil significantly more adverse events than placebo; most common SAEs: supraventricular arrhythmia and convulsions; should not be used routinely bcpt.12434

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Lader (1994) reviewed benzodiazepine dependence and described the withdrawal syndrome as comprising physical symptoms (photophobia, hyperacusis, unsteadiness, muscular spasm) and psychological symptoms (anxiety, insomnia, agitation)supported

    Review of BZD dependence; withdrawal syndrome described; flunitrazepam causing worldwide concern for abuse. pmid:7919947

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • History of substance use disorder: Elevated risk of misuse and dependence; the historical gel capsule injection crisis demonstrates this risk concretelypartially supported

    Review of BZD dependence; withdrawal syndrome described; flunitrazepam causing worldwide concern for abuse. pmid:7919947

  • Claim in safety — inconclusiveinconclusiveworking →

  • Elderly patients: Not an absolute contraindication, but increased pharmacodynamic sensitivity and fall risk warrant particular cautionsupported

    Meta-analysis: sedative hypnotics including zolpidem improve sleep statistically but magnitude small. Increased adverse event risk (falls, cognitive impairment) in over-60s. bmj.38623.768588.47

clinical-evidence22 · 0 ok

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

comparative-pharmacology16 · 0 ok

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

history14 · 1 ok

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Clinical practice guidelines from the American Academy of Sleep Medicine and the European Insomnia Guideline position benzodiazepines including temazepam as second-line pharmacotherapy after cognitive behavioral therapy for insomnia (CBT-I)supported

    CBT-I recommended first-line. Benzodiazepines and BZRAs (including zolpidem) can be used short-term (<=4 weeks). Longer-term use may be initiated in some cases weighing risks/benefits. jsr.14035

pharmacokinetic-detail14 · 1 ok

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • However, pharmacodynamic sensitivity increases with age, producing enhanced sedation, psychomotor impairment, and fall risk at any given plasma concentration.supported

    Review of insomnia pharmacotherapy in elderly; PK alterations, safety/efficacy of benzodiazepines, Z-drugs, melatonin agonists. j.clinthera.2016.09.010

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

pharmacology12 · 0 ok

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

summary12 · 1 ok

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Temazepam alone demonstrates relatively low acute lethality, but fatality risk increases substantially in combination with opioids, alcohol, or other CNS depressants. tolerance to the hypnotic effect develops within 2–3 weeks of continuous use, and physical-dependence produces a withdrawal syndrome comprising rebound-effect insomnia, autonomic hyperactivity, and — rarely — seizurespartially supported

    Review of BZD dependence; withdrawal syndrome described; flunitrazepam causing worldwide concern for abuse. pmid:7919947

  • Claim in summary — inconclusiveinconclusiveworking →

neuroscience10 · 0 ok

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

chemistry2 · 0 ok

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

receptor-pharmacology2 · 0 ok

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

3Sources

43 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
yearsourcetierstatusfeeds
2024Temazepam - Legal status by jurisdictionVarious regulatory agenciesurl:9b1fd1d1955cbb06weakconsumedcited only
2024Temazepam - StatPearlsStatPearls Publishingurl:df7e35eb3648b782weakconsumedcited only
2024Temazepam — PubChem CompoundPubChem · PubChempmid:5391moderateconsumedcited only
2024Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical TrialMendis R, Wong A, Frenkel S, et al. · Journal of palliative medicinepmid:39304187strongconsumed1 section
2024Temazepam physical/chemical properties (CAS 846-50-4)Chemical suppliersurl:81e07470b5a2b614weakconsumedcited only
2023The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023Riemann D, Espie CA, Altena E, et al. · Journal of Sleep Researchdoi:10.1111/jsr.14035moderateconsumed1 section
2018Pharmacological agents for improving sleep quality at high altitude: a systematic review and meta-analysis of randomized controlled trialsKong F, Liu G, Xu J · Sleep medicinedoi:10.1016/j.sleep.2018.06.017strongconsumedcited only
2017Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL · Journal of Clinical Sleep Medicinedoi:10.5664/jcsm.6470strongconsumedcited only
2017Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017Hiemke C, Bergemann N, Clement HW, et al. · Pharmacopsychiatrydoi:10.1055/s-0043-116492moderateconsumed1 section
2016Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses.Penninga EI, Graudal N, Ladekarl MB, Jürgens G · Basic & clinical pharmacology & toxicologydoi:10.1111/bcpt.12434strongconsumed1 section
2016Review of Safety and Efficacy of Sleep Medicines in Older AdultsSchroeck JL, Ford J, Conway EL, et al. · Clinical Therapeuticsdoi:10.1016/j.clinthera.2016.09.010moderateconsumed1 section
2014Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trialLähteenmäki R, Puustinen J, et al. · British journal of clinical pharmacologypmid:24286360strongconsumed2 sections
2013Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol useGudin JA, Mogali S, Jones JD, Comer SD · Postgraduate medicinedoi:10.3810/pgm.2013.07.2684moderateconsumed2 sections
2010Effect of hypnotic drugs on body balance and standing steadinessMets MA, Volkerts ER, Olivier B, Verster JC · Sleep medicine reviewsdoi:10.1016/j.smrv.2009.10.008strongconsumed1 section
2010Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPDStege G, Heijdra YF, van den Elshout FJ, et al. · Respiratory medicinedoi:10.1016/j.rmed.2009.10.022moderateconsumed2 sections
2008Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trialGlass JR, Sproule BA, Herrmann N, Busto UE · Journal of clinical psychopharmacologydoi:10.1097/jcp.0b013e31816a9e4fstrongconsumedcited only
2005Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefitsGlass JR, Lanctot KL, Herrmann N, Sproule B, Busto UE · BMJdoi:10.1136/bmj.38623.768588.47strongconsumed1 section
2004Comparison of temazepam 7.5 mg with temazepam 15 mg for the treatment of transient insomniaErman MK, Loewy D, Scharf MB · Current medical research and opinionpmid:15119980strongconsumed1 section
2004Temazepam capsules: what was the problem?Australian Prescriberurl:f4711ccff9a521e8weakconsumedcited only
2004Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled studyVoshaar RC, van Balkom AJ, Zitman FG · European neuropsychopharmacologypmid:15163440strongconsumed2 sections
2001Drug related deaths in the Strathclyde region of Scotland, 1995-1998Seymour A, Black M, Oliver JS · Forensic science internationalpmid:11587866moderateconsumed1 section
1999A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experienceHajak G · Drug safetypmid:10612270moderateconsumed1 section
1996Sedative-hypnotic drugs and the risk of hip fractureWysowski DK, Baum C, Ferguson WJ, Lundin F, Ng MJ, Hammerstrom T · Journal of clinical epidemiologypmid:8598503moderateconsumed2 sections
1994Anxiolytic drugs: dependence, addiction and abuseLader M · European neuropsychopharmacologypmid:7919947moderateconsumed2 sections
1994Limb ischaemia after intra-arterial injection of Temazepam gel: histology of nine casesDodd TJ, Scott RN, Woodburn KR, Going JJ · Journal of clinical pathologypmid:8063932weakconsumed2 sections
1993Bioavailability of temazepam: comparison of four 7.5-MG capsules with a single 30-MG capsuleAbolin C, Hwang DS, Mazza F · The Annals of pharmacotherapypmid:8329784moderateconsumed1 section
1993Intra-arterial injection of temazepam in drug abusersNott DM, Chandrasekar R, Enabi L, Greaney M, Bakran A, Harris PL · European journal of vascular surgerypmid:8454086weakconsumed2 sections
1992A double-blind comparison of the effects of temazepam and triazolam on residual, daytime performance in elderly insomniacsNakra BR, Gfeller JD, Hassan R · International psychogeriatricspmid:1391671strongconsumed2 sections
1991Adrenergic modulation of preoperative anxiety: a comparison of temazepam, clonidine, and timololCarabine UA, Milligan KR, Moore JA · Anesthesia and analgesiapmid:1683183strongconsumed2 sections
1991Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the ElderlyGreenblatt DJ, Harmatz JS, Shader RI · Clinical Pharmacokineticsdoi:10.2165/00003088-199121030-00002moderateconsumed5 sections
Show all 43 sources — 13 more
Sources 31 to 43
yearsourcetierstatusfeeds
1990A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomniaNgen CC, Hassan R · International clinical psychopharmacologypmid:2230060strongconsumed1 section
1989Effects of temazepam premedication on cognitive recovery following alfentanil-propofol anaesthesiaBailie R, Christmas L, Price N, Restall J, Simpson P, Wesnes K · British journal of anaesthesiapmid:2569887strongconsumed3 sections
1987Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three monthsAllen RP, Mendels J, Nevins DB, Chernik DA, Hoddes E · Journal of clinical pharmacologypmid:2892863strongconsumed3 sections
1987Pharmacokinetics of temazepam after day-time and night-time oral administrationMüller FO, Van Dyk M, Hundt HK, Joubert AL, Luus HG, Groenewoud G, Dunbar GC · European journal of clinical pharmacologypmid:2891534moderateconsumed1 section
1986Quazepam and temazepam: effects of short- and intermediate-term use and withdrawalKales A, Bixler EO, Soldatos CR, et al. · Clinical pharmacology and therapeuticspmid:2868823strongconsumed4 sections
1985Effects of end-stage renal disease and aluminum hydroxide on temazepam kineticsKroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP · Clinical pharmacology and therapeuticspmid:2858279moderateconsumed2 sections
1984Hypnotic action of benzodiazepines: a possible mechanismChweh AY, Lin YB, Swinyard EA · Life sciencespmid:6145073moderateconsumed1 section
1983Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effectsKales A, Kales JD · Journal of clinical psychopharmacologypmid:6132933moderateconsumed3 sections
1982Benzodiazepine withdrawal syndrome: a literature review and evaluationMacKinnon GL, Parker WA · The American journal of drug and alcohol abusepmid:6133446moderateconsumed1 section
1982Temazepam as premedication in elderly patientsClark G, Erwin D, Yate P, Burt D, Major E · Anaesthesiapmid:6123281strongconsumed2 sections
1979Bioavailability of temazepam in soft gelatin capsulesFuccella LM · British journal of clinical pharmacologypmid:41540moderateconsumedcited only
1979Pharmacokinetics and metabolism of temazepam in man and several animal speciesSchwarz HJ · British journal of clinical pharmacologypmid:41539moderateconsumed4 sections
1977Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsulesFuccella LM, Bolcioni G, Tamassia V, Ferrario L, Tognoni G · European journal of clinical pharmacologypmid:598411moderateconsumed2 sections

4Docket

one filing per activity — decisions, correspondence, reports

awaiting ruling — 1

  • dependence · taper2026-07-03
  1. 0012026-05-09revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/temazepam/version/1
  2. 0022026-06-04proposal31 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    31 items in this filing

    • contraindication · immunological
    • contraindication · other
    • contraindication · respiratory
    • contraindication · hepatic
    • contraindication · neurological
    • contraindication · other
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · age
    • contraindication · other
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · peak
    • timeline · oral · plateau
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    psx:substance/temazepam/proposal/contraindication/0b1f8dbc-dd00-4fbd-a776-596dff2895bf
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/temazepam/pub/5e2ce35e-62b5-4a3e-80be-13d488ece90c

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_card25c55f1c618b1f43fee4eaaa…2026-10-19 20:34Revision 1current
emergencydcd2ca271fbe095dc7fb6211…2026-09-04 04:32Revision 1current
info_card833f2165fa6a7124a2be8626…2026-09-04 04:32Revision 1superseded2026-10-19
noticef86dcbf2f96f986353594463…2026-09-04 04:32Revision 1current